Great partner- but cheapish entry. No more Phase II funding worries when they get there. It's results now that matter as always
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025